Matches in SemOpenAlex for { <https://semopenalex.org/work/W2442537192> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2442537192 endingPage "30" @default.
- W2442537192 startingPage "323" @default.
- W2442537192 abstract "The possible advantage of adding cisplatin (P) to cyclophosphamide (C) + adriamycin (A) in the management of stages III and IV ovarian cancer of epithelial origin was tested in a trial in which 149 patients were randomized to receive, after initial surgery, either CAP (C = 600 mg/sqm, A = 45 mg/sqm, P = 50 mg/sqm) or CA (C = 600 mg/sqm, A = 45 mg/sqm) every 4 weeks for 6 to 12 cycles, at which time follow-up laparotomoy was to be performed in responding or clinically disease-free patients. Fifteen patients were not included in the final analysis and the remaining 134 patients were considered fully or partially evaluable and are used in analysis of response and survival. The complete and partial response rates were 45.6% in the CAP arm and 45.4% in the CA arm, but the CAP regimen is of special importance in patients with bulky disease. Median survival CAP = 24 m and CA = 24.2 m), time to progression and survival was found not significantly different when CAP and CA were compared. However, more patients in the CA regimen had no macroscopic disease left after surgery than in CAP regimen (11 versus 6) and more patients in the CAP arm dose reductions and schedule delays than in the CA arm (61.1% versus 38.2%)." @default.
- W2442537192 created "2016-06-24" @default.
- W2442537192 creator A5008484056 @default.
- W2442537192 creator A5027141013 @default.
- W2442537192 creator A5030989495 @default.
- W2442537192 creator A5035726892 @default.
- W2442537192 creator A5035983923 @default.
- W2442537192 creator A5037591767 @default.
- W2442537192 creator A5044702944 @default.
- W2442537192 creator A5052430948 @default.
- W2442537192 creator A5064114944 @default.
- W2442537192 creator A5084115298 @default.
- W2442537192 date "1990-01-01" @default.
- W2442537192 modified "2023-10-11" @default.
- W2442537192 title "Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study." @default.
- W2442537192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2097149" @default.
- W2442537192 hasPublicationYear "1990" @default.
- W2442537192 type Work @default.
- W2442537192 sameAs 2442537192 @default.
- W2442537192 citedByCount "6" @default.
- W2442537192 countsByYear W24425371922022 @default.
- W2442537192 crossrefType "journal-article" @default.
- W2442537192 hasAuthorship W2442537192A5008484056 @default.
- W2442537192 hasAuthorship W2442537192A5027141013 @default.
- W2442537192 hasAuthorship W2442537192A5030989495 @default.
- W2442537192 hasAuthorship W2442537192A5035726892 @default.
- W2442537192 hasAuthorship W2442537192A5035983923 @default.
- W2442537192 hasAuthorship W2442537192A5037591767 @default.
- W2442537192 hasAuthorship W2442537192A5044702944 @default.
- W2442537192 hasAuthorship W2442537192A5052430948 @default.
- W2442537192 hasAuthorship W2442537192A5064114944 @default.
- W2442537192 hasAuthorship W2442537192A5084115298 @default.
- W2442537192 hasConcept C121608353 @default.
- W2442537192 hasConcept C126322002 @default.
- W2442537192 hasConcept C126894567 @default.
- W2442537192 hasConcept C141071460 @default.
- W2442537192 hasConcept C143998085 @default.
- W2442537192 hasConcept C168563851 @default.
- W2442537192 hasConcept C2776694085 @default.
- W2442537192 hasConcept C2776755627 @default.
- W2442537192 hasConcept C2778239845 @default.
- W2442537192 hasConcept C2780427987 @default.
- W2442537192 hasConcept C2781303535 @default.
- W2442537192 hasConcept C2781413609 @default.
- W2442537192 hasConcept C71924100 @default.
- W2442537192 hasConcept C90924648 @default.
- W2442537192 hasConceptScore W2442537192C121608353 @default.
- W2442537192 hasConceptScore W2442537192C126322002 @default.
- W2442537192 hasConceptScore W2442537192C126894567 @default.
- W2442537192 hasConceptScore W2442537192C141071460 @default.
- W2442537192 hasConceptScore W2442537192C143998085 @default.
- W2442537192 hasConceptScore W2442537192C168563851 @default.
- W2442537192 hasConceptScore W2442537192C2776694085 @default.
- W2442537192 hasConceptScore W2442537192C2776755627 @default.
- W2442537192 hasConceptScore W2442537192C2778239845 @default.
- W2442537192 hasConceptScore W2442537192C2780427987 @default.
- W2442537192 hasConceptScore W2442537192C2781303535 @default.
- W2442537192 hasConceptScore W2442537192C2781413609 @default.
- W2442537192 hasConceptScore W2442537192C71924100 @default.
- W2442537192 hasConceptScore W2442537192C90924648 @default.
- W2442537192 hasIssue "5" @default.
- W2442537192 hasLocation W24425371921 @default.
- W2442537192 hasOpenAccess W2442537192 @default.
- W2442537192 hasPrimaryLocation W24425371921 @default.
- W2442537192 hasRelatedWork W1993377100 @default.
- W2442537192 hasRelatedWork W2008634739 @default.
- W2442537192 hasRelatedWork W2042515268 @default.
- W2442537192 hasRelatedWork W2055272681 @default.
- W2442537192 hasRelatedWork W2145130154 @default.
- W2442537192 hasRelatedWork W2402057014 @default.
- W2442537192 hasRelatedWork W2411094976 @default.
- W2442537192 hasRelatedWork W2434089007 @default.
- W2442537192 hasRelatedWork W2530877275 @default.
- W2442537192 hasRelatedWork W4234586607 @default.
- W2442537192 hasVolume "11" @default.
- W2442537192 isParatext "false" @default.
- W2442537192 isRetracted "false" @default.
- W2442537192 magId "2442537192" @default.
- W2442537192 workType "article" @default.